Summary
Signal counts
Assets tracked: 10
Watchlist assets: 7
Registry stop assets: 1
Sponsor overview
Memorial Sloan Kettering Cancer Center
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00591851 | https://clinicaltrials.gov/study/NCT00024258 | https://clinicaltrials.gov/study/NCT05024994 | https://clinicaltrials.gov/study/NCT03420508 | https://clinicaltrials.gov/study/NCT03241745 | https://clinicaltrials.gov/study/NCT03038672 | https://clinicaltrials.gov/study/NCT03465592 | https://clinicaltrials.gov/study/NCT03668119 | https://clinicaltrials.gov/study/NCT02960906 | https://clinicaltrials.gov/study/NCT03195478 | https://clinicaltrials.gov/study/NCT03285321 | https://clinicaltrials.gov/study/NCT02866383 | https://clinicaltrials.gov/study/NCT04493203 | https://clinicaltrials.gov/study/NCT06582771 | https://clinicaltrials.gov/study/NCT01025453 | https://clinicaltrials.gov/study/NCT00466531 | https://clinicaltrials.gov/study/NCT03879811 | https://clinicaltrials.gov/study/NCT03704688
Assets
Linked programs
- AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P): Low Signal (0/5)
- arsenic trioxide: Watchlist Signal (2/5)
- E7820: Low Signal (0/5)
- Ensartinib: Watchlist Signal (2/5)
- Nivolumab: Operational Burden Signal (4/5)
- Sotorasib: Watchlist Signal (2/5)
- Temsirolimus and Sorafenib: Watchlist Signal (2/5)
- therapeutic autologous lymphocytes: Low Signal (1/5)
- TMZ: Registry Stop Signal (3/5)
- Trametinib 0.5 mg: Watchlist Signal (2/5)